SNIPR Biome receives funding for the development of CRISPR-medicines to improve Environmental Enteric Dysfunction (EED) in pregnant women
June 28, 2024 02:50 ET
|
SNIPR BIOME
SNIPR BIOME receives funding from the Bill & Melinda Gates Foundation to accelerate the development of SNIPR Biome's microbial gene therapy platform.
CRISPR and Cas Genes Market Research 2024 - Global Industry Size, Share, Trends, Opportunity, & Forecast, 2019-2029F
June 20, 2024 07:24 ET
|
Research and Markets
Dublin, June 20, 2024 (GLOBE NEWSWIRE) -- The "CRISPR and Cas Genes Market - Global Industry Size, Share, Trends, Opportunity, & Forecast, 2019-2029F" report has been added to ...
Global Genome Editing Market Size, Share & Trends Analysis Report by Technology (CRISPR/Cas9, ZFN), Delivery Method (Ex-vivo, In-vivo) 2024-2030
June 18, 2024 10:19 ET
|
Research and Markets
Dublin, June 18, 2024 (GLOBE NEWSWIRE) -- The "Global Genome Editing Market Size, Share & Trends Analysis Report by Technology (CRISPR/Cas9, ZFN), Delivery Method (Ex-vivo, In-vivo),...
CRISPR Therapies Market Research 2024: Pipeline Analysis, Therapeutic Assessment, Unmet Needs, Impact of Drugs
June 14, 2024 06:15 ET
|
Research and Markets
Dublin, June 14, 2024 (GLOBE NEWSWIRE) -- The "CRISPR therapies - Pipeline Insight, 2024" drug pipelines has been added to ResearchAndMarkets.com's offering.This "CRISPR Therapies - Pipeline...
CRISPR Technology Global Strategic Research Report 2024
June 14, 2024 05:30 ET
|
Research and Markets
Dublin, June 14, 2024 (GLOBE NEWSWIRE) -- The "CRISPR Technology - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.The global market for CRISPR...
Caribou Biosciences Presents Encouraging Clinical Data from CB-010 ANTLER Phase 1 Trial in Second-line LBCL Patients at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
June 02, 2024 19:00 ET
|
Caribou Biosciences, Inc.
-- CB-010 allogeneic CAR-T cell therapy with partial HLA matching has potential to rival efficacy and safety profile of approved autologous CAR-T cell therapies -- -- 14.4 months median PFS in ANTLER...
Caribou Biosciences to Host KOL Discussion with Webcast from the 2024 ASCO Annual Meeting and Participate in Upcoming Investor Conferences
May 30, 2024 16:01 ET
|
Caribou Biosciences, Inc.
BERKELEY, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the company’s...
Power of Recursion OS on Display at Genome Scale in Nature Genetics Paper Detailing Potential Limitation of CRISPR Gene Editing Tool
May 29, 2024 15:27 ET
|
Recursion Pharmaceuticals
SALT LAKE CITY, May 29, 2024 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today published in Nature...
Cytosurge's CellEDIT Workflow, based on its Proprietary FluidFM® Technology, Receives Validation in Peer-Reviewed Publication
May 29, 2024 08:30 ET
|
Cytosurge AG
CellEDIT uses FluidFM for precise nuclear CRISPR/Cas9 injection, boosting efficiency by controlling RNP amounts, preserving traits in edited CHO-K1 cells.
Cytosurge's CellEDIT Workflow, based on its Proprietary FluidFM® Technology, Receives Validation in Peer-Reviewed Publication
May 29, 2024 02:30 ET
|
Cytosurge AG
CellEDIT uses FluidFM for precise nuclear CRISPR/Cas9 injection, boosting efficiency by controlling RNP amounts, preserving traits in edited CHO-K1 cells.